Is BPC-157 Legal? FDA, Compounding and WADA Status
BPC-157's FDA status, compounding rules and anti-doping status, with a dated timeline of every change we track.
- FDA status
- Not approved
- Off Category 2, 15 Apr 2026
- PCAC vote
- 8–6 for 503A
- Jul 2026, not final
- WADA
- Prohibited (S0)
- In and out of competition
Current status
PCAC voted 8–6 for 503A (Jul 2026)No. BPC-157 is not FDA approved for any use. The FDA removed it from Category 2 on 15 Apr 2026. Its advisory committee voted 8–6 in July 2026 to add it to the 503A compounding list. That vote is not final.
| Country | Status | Source |
|---|---|---|
| United States | No approved product foundNo FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "BPC-157" returned no matches on 2 Oct 2026. | api.fda.govchecked 2 Oct 2026 |
Timeline
- Advisory committee backs 6 of 7 peptides for the 503A listPCAC vote
- FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA
Compounding and research-use sellers
- Category 2 is the FDA's list of bulk substances it flagged as raising significant safety concerns. Compounding pharmacies are not expected to compound from them while they are on it.
- The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which substances belong on the 503A bulks list that pharmacies may compound from. Its votes are advice; the FDA decides.
- "Research use only" products are sold outside these rules and are not checked by the FDA for identity, purity or dose.
- BPC-157 was removed from Category 2 on 15 Apr 2026. Removal is not approval.
FDA compounding record: BPC-157 was removed from FDA's 503A category 2 because the nominators withdrew; FDA announced a Pharmacy Compounding Advisory Committee consultation on 23 July 2026 on whether to add it to the 503A bulks list. · fda.gov, checked 2 Oct 2026
Sport and drug testing
Prohibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition.
Outside the US
Rules differ by country. What each regulator's own records show, with the date we checked:
| Country | Status | Source |
|---|---|---|
| United Kingdom | No approved product foundNo approved product found in an emc (UK SmPC compendium) search for "BPC-157" on 2 Oct 2026. | medicines.org.ukchecked 2 Oct 2026 |
| Canada | No approved product foundNo product found in a Health Canada Drug Product Database search for ingredient "BPC-157" on 2 Oct 2026. | health-products.canada.cachecked 2 Oct 2026 |
| European Union | No centrally authorised EU medicine foundEMA medicines list, searched 2 Oct 2026 | ema.europa.euchecked 2 Oct 2026 |
What FDA records say about BPC-157
FDA Drugs@FDA returns nothing for the active ingredient BPC-157: the query in the cached record came back as not found.[4]
In FDA’s safety-risk table for withdrawn nominations, the BPC-157 entry says the agency found little safety information and cannot tell whether the drug would harm people.[11]
The same entry flags immunogenicity and peptide-related impurities as concerns for compounded BPC-157.[11]
FDA describes Category 2 as the tier for nominated substances where it has identified significant safety risks in compounding pending further evaluation; unlike Category 1, FDA does not intend to adopt the Category 1 policy for them.[12]
What changed in 2026
In April, FDA gave notice that BPC-157 would leave Category 2 because the nominations were withdrawn by the nominators, while announcing a PCAC consultation on 23 July 2026 about BPC-157 acetate and the free base.[13]
FDA elected to proceed with presenting BPC-157 free base and BPC-157 acetate to the PCAC even though the nominations had been withdrawn.[14]
FDA's meeting page lists ulcerative colitis as the use evaluated for BPC-157 free base and acetate.[15]
FDA staff went into the meeting proposing that the free base not go on the 503A list.[14]
The committee was asked to vote on whether BPC-157 acetate should be placed on the list, separately from the free base.[16]
What is still pending
FDA said it will not issue a final determination until the advisory committee input has been considered and all reviews have been finalized.[14]
Under 503A, a bulk substance must meet a USP or NF monograph, be a component of an FDA-approved drug, or appear on the 503A bulks list. For BPC-157 only the last route is open.[12]
Sport
WADA names BPC-157 in S0, the class of non-approved substances prohibited at all times.[3]
Common questions
Is BPC-157 FDA approved?
No. FDA’s drug database search returned no match, and the EMA medicines export lists no BPC-157 medicine.[8]
Is BPC-157 legal to buy?
BPC-157 is not an approved drug: FDA's slides state it is not a component of an approved product in any country. Whether it can be compounded is unsettled, because FDA has treated it as a safety-risk substance and the bulks-list decision is still pending (see the sections above). WADA separately prohibits it for athletes.[17]
Is BPC-157 banned by WADA?
Yes. Prohibited by WADA (S0), in and out of competition.
Did FDA ban BPC-157?
FDA did not ban it in the records here. It listed BPC-157 as a safety-risk substance, then gave notice of removal after the nominators withdrew; that tier means FDA would consider enforcement against compounders, not that a ban order was issued.[12]
Is BPC-157 in Category 1?
The April notice lists BPC-157 under removals from the safety-risk category and then announces a PCAC consultation. It does not add the substance to the list under evaluation.[13]
Is BPC-157 legal in the UK?
The UK's electronic medicines compendium returned no search results for BPC-157, so no UK-licensed BPC-157 medicine turned up there. That is a statement about licensed products and says nothing about possession or sale law.[6]
More on BPC-157
Sources
- 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2Pharmacy Compounding Advisory Committee meeting, 23–24 Jul 2026 (agenda and materials)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 4United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "BPC-157" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 5US compounding: BPC-157 was removed from FDA's 503A category 2 because the nominators withdrew; FDA announced a Pharmacy Compounding Advisory Committee consultation on 23 July 2026 on whether to add it to the 503A bulks list.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 6United Kingdom: No approved product found in an emc (UK SmPC compendium) search for "BPC-157" on 2 Oct 2026.Electronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
- 7Canada: No product found in a Health Canada Drug Product Database search for ingredient "BPC-157" on 2 Oct 2026.Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
- 8EMA medicines export (centrally authorised medicines) (searched 2 Oct 2026)European Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
- 9Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 10FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 11Official web pageOfficial web page · web page
- 12Official web pageOfficial web page · web page
- 13Official web pageOfficial web page · web page
- 14Official web pageOfficial web page · web page
- 15Official web pageOfficial web page · web page
- 16Official web pageOfficial web page · web page
- 17Official web pageOfficial web page · web page
Found an error? Report a correction.